Incyte Corporation
08/31/2026 | Press release | Distributed by Public on 08/31/2026 14:29
Material Event (Form 8-K)
Item 8.01 Other Events.
Incyte Corporation (the "Company") today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services ("CMS") intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation.
Under the agreement, the Company will enable state Medicaid programs to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations. Additionally, the Company expects that it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. The Company does not expect the agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook.
2
Incyte Corporation published this content on August 31, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 31, 2026 at 20:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]